CGTLive’s Weekly Rewind – November 11, 2022

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. CRISPR-CAR T Therapy Yields First Allogeneic Complete Response in R/R Solid Tumors

Data from the COBALT-RCC study in renal cell carcinoma were presented at SITC 2022.

2. Susan Foy, PhD, on Evaluating Personalized, Neoantigen-Specific T Cell Therapy in Solid Tumors

The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.

3. Gene Expression Profiles Characterize CAR T-Cells in Solid and Hematological Tumors

Further analysis will be performed to elucidate which characteristics correlate with optimal cell therapy behavior.

4. Samir Parekh, MD, on Surprising Efficacy of Sequential T-Cell Redirection Therapy in Multiple Myeloma

The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.

5. BioMarin Prepares for PDUFA Delay for Val-Rox Hemophilia Gene Therapy

Recent communication with the FDA suggests that the agency's decision might be delayed past Q1 2023.